HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, T. H. Articles by Schreiber, H. Search for Related Content PubMed PubMed Citation Articles by Wu, T. H. Articles by Schreiber, H.

Long-Term Suppression of Tumor Growth by TNF Requires a Stat1- and IFN Regulatory Factor 1-Dependent IFN- Pathway but Not IL-12 or IL-18¹

Terry H. Wu^2,*, Christine N. Pabin^*, Zhihai Qin, Thomas Blankenstein^,¶, Mary Philip, James Dignam, Karin Schreiber^* and Hans Schreiber^*,

^* Department of Pathology, Committee on Cancer Biology, Department of Health Studies, University of Chicago, Chicago, IL 60637; Institute of Immunology, Free University of Berlin, Berlin, Germany; and ^¶ Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

Tumor cells engineered to secrete TNF were used as a model to examine how persistently high local concentrations of TNF suppress tumor growth. TNF secretion had no effect on tumor cell proliferation in vitro but caused a very impressive growth arrest in vivo that was dependent on both bone marrow- and non-bone marrow-derived host cells expressing TNFR. Suppression also required an endogenous IFN- pathway consisting minimally of IFN-, IFN- receptor, Stat1, and IFN regulatory factor 1 since mice with targeted disruption of any of the four genes failed to arrest tumor growth. The ability of these mice to suppress tumor growth was restored after they were reconstituted with bone marrow cells from Wt mice. Interestingly, mice lacking the major IFN--inducing cytokines IL-12 and IL-18 or T cells, B cells, and the majority of NK cells that are potential sources of IFN- nevertheless inhibited tumor development. Moreover, multiple lines of evidence indicated that local release of IFN- was not required to inhibit tumor formation. These results strongly suggest a novel function for the endogenous IFN- pathway that without measurable IFN- production or activity affects the ability of TNF to suppress tumor development.

This article has been cited by other articles:

				Y. Lu, W. Yang, C. Qin, L. Zhang, J. Deng, S. Liu, and Z. Qin Responsiveness of Stromal Fibroblasts to IFN-{gamma} Blocks Tumor Growth via Angiostasis J. Immunol., November 15, 2009; 183(10): 6413 - 6421. [Abstract] [Full Text] [PDF]

				T. Hagemann, S. K. Biswas, T. Lawrence, A. Sica, and C. E. Lewis Regulation of macrophage function in tumors: the multifaceted role of NF-{kappa}B Blood, April 2, 2009; 113(14): 3139 - 3146. [Abstract] [Full Text] [PDF]

				D. Li, Y. Li, X. Wu, Q. Li, J. Yu, J. Gen, and X.-L. Zhang Knockdown of Mgat5 Inhibits Breast Cancer Cell Growth with Activation of CD4+ T Cells and Macrophages J. Immunol., March 1, 2008; 180(5): 3158 - 3165. [Abstract] [Full Text] [PDF]

				S. Zhu, M. Waguespack, S. A. Barker, and S. Li Doxorubicin Directs the Accumulation of Interleukin-12 Induced IFN{gamma} into Tumors for Enhancing STAT1 Dependent Antitumor Effect Clin. Cancer Res., July 15, 2007; 13(14): 4252 - 4260. [Abstract] [Full Text] [PDF]

				X. Zhao, M. Mohaupt, J. Jiang, S. Liu, B. Li, and Z. Qin Tumor Necrosis Factor Receptor 2-Mediated Tumor Suppression Is Nitric Oxide Dependent and Involves Angiostasis Cancer Res., May 1, 2007; 67(9): 4443 - 4450. [Abstract] [Full Text] [PDF]